中东呼吸综合征是由冠状病毒MERS-coronavirus引起的急性重症肺炎。该疾病具有较高的病死率，在无有效疫苗的情况下，病人来源的单克隆应急救治抗体是防控重要手段。目前国际上的抗体大部分识别RBD区域，但易受病毒变异影响。S区域上较为保守的NTD和S2区域也可诱导中和抗体产生，但该部分抗体的研究较少。本团队前期合作研发国际首个MERS病人来源的应急救治保护性单克隆抗体LCA60，并利用本团队研发国际首个MERS小鼠动物模型证明该抗体有良好保护性。基于前期研究，本项目建立高效的人源抗体筛选平台，研发识别MERS-CoV S蛋白RBD，NTD，S2多个区域的应急救治抗体库；多种识别区域抗体协同作用从而加强中和作用能力，提高保护效果。该课题研究不但可以为疫苗的研发提供新的参考靶点及策略，同时也丰富了多结构区域的全人源中和抗体库，对该疾病的防控做出巨大贡献。

Middle East Respiratory Syndrome (MERS) is caused by Middle East Respiratory Syndrome coronavirus (MERS-CoV). Administration of protective monoclonal antibodies derived from convalescent MERS patients is a potent prophylactic and therapeutic treatment against lethal MERS-CoV infection. Currently, most of antibodies target the Receptor Binding Domain (RBD) of MERS-CoV spike protein, the domain is prone to mutation. While S1 domain to the N terminal (NTD) and S2 domain are more conservative and are also recognized by neutralizing antibodies, however, less studies of NTD and S2 humanized monoclonal antibodies have been reported. In our study, we will optimize the EBV transformation platform and immortalize human memory B cells from PBMC and generate novel protective monoclonal antibodies targeting RBD, NTD and S2 domain respectively. Monoclonal antibodies targeting diverse domain have a cooperativity effect on improving neutralization and protection. This research can not only provide a new reference target and strategy for vaccine research and development, but also enrich the whole human neutralizing antibody library in the diverse domain, making a great contribution to the prevention and control of this disease all over the world.